RedHill Biopharma Ltd.

NasdaqGM:RDHL Stock Report

Mkt Cap: US$20.5m

RedHill Biopharma Future Growth

How is RedHill Biopharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


50.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGM:RDHL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202538-6-9-21
12/31/202421-23-24-171
12/31/20239-44-27-151
9/30/202271-92-42-42N/A
6/30/202275-78-55-55N/A
3/31/202278-95-57-57N/A
12/31/202186-98-65-65N/A
9/30/202185-98-63-63N/A
6/30/202184-95-54-54N/A
3/31/202184-82-103-50N/A
12/31/202064-76-102-49N/A
9/30/202044-64-104-50N/A
6/30/202025-55-102-48N/A
3/31/20206-50-45-44N/A
12/31/20196-42-41-41N/A
9/30/20196-38-35-35N/A
6/30/20197-39-35-35N/A
3/31/20198-39-33-32N/A
12/31/20188-39-35-34N/A
9/30/20189-42-40-40N/A
6/30/20188-47-44-43N/A
3/31/20186-47-45-44N/A
12/31/20174-46-46-45N/A
9/30/20172-43-42-41N/A
6/30/20171-37-38-38N/A
3/31/20170-32-34-34N/A
12/31/20160-29-28-28N/A
9/30/20160-28-24-24N/A
6/30/20160-22N/A-20N/A
3/31/20160-22N/A-19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RDHL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RDHL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RDHL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RDHL's revenue is expected to decline over the next 3 years (-0.8% per year).

High Growth Revenue: RDHL's revenue is forecast to decline over the next 3 years (-0.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RDHL's Return on Equity is forecast to be high in 3 years time


Discover growth companies